IBDEI1WN ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,33498,2)
 ;;=^5019541
 ;;^UTILITY(U,$J,358.3,33499,0)
 ;;=R63.4^^182^2004^27
 ;;^UTILITY(U,$J,358.3,33499,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33499,1,3,0)
 ;;=3^Abnormal Weight Loss
 ;;^UTILITY(U,$J,358.3,33499,1,4,0)
 ;;=4^R63.4
 ;;^UTILITY(U,$J,358.3,33499,2)
 ;;=^5019542
 ;;^UTILITY(U,$J,358.3,33500,0)
 ;;=R63.5^^182^2004^26
 ;;^UTILITY(U,$J,358.3,33500,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33500,1,3,0)
 ;;=3^Abnormal Weight Gain
 ;;^UTILITY(U,$J,358.3,33500,1,4,0)
 ;;=4^R63.5
 ;;^UTILITY(U,$J,358.3,33500,2)
 ;;=^5019543
 ;;^UTILITY(U,$J,358.3,33501,0)
 ;;=R64.^^182^2004^44
 ;;^UTILITY(U,$J,358.3,33501,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33501,1,3,0)
 ;;=3^Cachexia
 ;;^UTILITY(U,$J,358.3,33501,1,4,0)
 ;;=4^R64.
 ;;^UTILITY(U,$J,358.3,33501,2)
 ;;=^17920
 ;;^UTILITY(U,$J,358.3,33502,0)
 ;;=R68.3^^182^2004^48
 ;;^UTILITY(U,$J,358.3,33502,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33502,1,3,0)
 ;;=3^Clubbing of Fingers
 ;;^UTILITY(U,$J,358.3,33502,1,4,0)
 ;;=4^R68.3
 ;;^UTILITY(U,$J,358.3,33502,2)
 ;;=^5019553
 ;;^UTILITY(U,$J,358.3,33503,0)
 ;;=R73.01^^182^2004^84
 ;;^UTILITY(U,$J,358.3,33503,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33503,1,3,0)
 ;;=3^Impaired Fasting Glucose
 ;;^UTILITY(U,$J,358.3,33503,1,4,0)
 ;;=4^R73.01
 ;;^UTILITY(U,$J,358.3,33503,2)
 ;;=^5019561
 ;;^UTILITY(U,$J,358.3,33504,0)
 ;;=R73.02^^182^2004^85
 ;;^UTILITY(U,$J,358.3,33504,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33504,1,3,0)
 ;;=3^Impaired Glucose Tolerance (oral)
 ;;^UTILITY(U,$J,358.3,33504,1,4,0)
 ;;=4^R73.02
 ;;^UTILITY(U,$J,358.3,33504,2)
 ;;=^5019562
 ;;^UTILITY(U,$J,358.3,33505,0)
 ;;=R73.09^^182^2004^13
 ;;^UTILITY(U,$J,358.3,33505,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33505,1,3,0)
 ;;=3^Abnormal Glucose NEC
 ;;^UTILITY(U,$J,358.3,33505,1,4,0)
 ;;=4^R73.09
 ;;^UTILITY(U,$J,358.3,33505,2)
 ;;=^5019563
 ;;^UTILITY(U,$J,358.3,33506,0)
 ;;=R73.9^^182^2004^80
 ;;^UTILITY(U,$J,358.3,33506,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33506,1,3,0)
 ;;=3^Hyperglycemia,Unspec
 ;;^UTILITY(U,$J,358.3,33506,1,4,0)
 ;;=4^R73.9
 ;;^UTILITY(U,$J,358.3,33506,2)
 ;;=^5019564
 ;;^UTILITY(U,$J,358.3,33507,0)
 ;;=R76.11^^182^2004^136
 ;;^UTILITY(U,$J,358.3,33507,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33507,1,3,0)
 ;;=3^Positive PPD
 ;;^UTILITY(U,$J,358.3,33507,1,4,0)
 ;;=4^R76.11
 ;;^UTILITY(U,$J,358.3,33507,2)
 ;;=^5019570
 ;;^UTILITY(U,$J,358.3,33508,0)
 ;;=R79.1^^182^2004^3
 ;;^UTILITY(U,$J,358.3,33508,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33508,1,3,0)
 ;;=3^Abnormal Coagulation Profile
 ;;^UTILITY(U,$J,358.3,33508,1,4,0)
 ;;=4^R79.1
 ;;^UTILITY(U,$J,358.3,33508,2)
 ;;=^5019591
 ;;^UTILITY(U,$J,358.3,33509,0)
 ;;=R82.5^^182^2004^65
 ;;^UTILITY(U,$J,358.3,33509,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33509,1,3,0)
 ;;=3^Elevated Urine Levels of Drug/Meds/Biol Subst
 ;;^UTILITY(U,$J,358.3,33509,1,4,0)
 ;;=4^R82.5
 ;;^UTILITY(U,$J,358.3,33509,2)
 ;;=^5019605
 ;;^UTILITY(U,$J,358.3,33510,0)
 ;;=R82.6^^182^2004^24
 ;;^UTILITY(U,$J,358.3,33510,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33510,1,3,0)
 ;;=3^Abnormal Urine Levels of Subst of Nonmed Source
 ;;^UTILITY(U,$J,358.3,33510,1,4,0)
 ;;=4^R82.6
 ;;^UTILITY(U,$J,358.3,33510,2)
 ;;=^5019606
 ;;^UTILITY(U,$J,358.3,33511,0)
 ;;=R82.7^^182^2004^25
 ;;^UTILITY(U,$J,358.3,33511,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33511,1,3,0)
 ;;=3^Abnormal Urine Microbiological Findings
 ;;^UTILITY(U,$J,358.3,33511,1,4,0)
 ;;=4^R82.7
 ;;^UTILITY(U,$J,358.3,33511,2)
 ;;=^5019607
 ;;^UTILITY(U,$J,358.3,33512,0)
 ;;=R82.8^^182^2004^21
 ;;
 ;;$END ROU IBDEI1WN
